论文部分内容阅读
[目的]比较食管腺癌单纯手术与合并术前化疗的预后。[方法]单纯手术组91例，术前DDP，5FU联合化疗组16例，术前VP16、ADM、DDP联合化疗组22例，比较3组的生存率。[结果]单纯手术组91例手术死亡率2％，2年生存率24％，4年生存率8％。术前DDP、5FU联合化疗组16例，化疗后完全缓解1例（16％），部分缓解5例（31％），无效10例（63％），12例手术切除，1例由于化疗有关死亡，1例手术死亡，2、4年生存率均为42％。术前DDP、ADM、VP16联合化疗组22例，化疗后1例完全缓解（5％），11例部分缓解（50％），10倒无效（45％），18例手术切除，无手术死亡，2年生存率58％。[结论]术前化疗能明显提高食管腺癌病人的生存率，同时治疗应个体化。
[Objective] To compare the prognosis of simple surgery and preoperative chemotherapy for esophageal adenocarcinoma. [Methods] 91 patients in the simple surgery group, 16 patients with preoperative DDP and 5FU combined with chemotherapy, and 22 patients with VP16, ADM and DDP combined with chemotherapy before operation were compared. The survival rate of the 3 groups was compared. [Results] The operative mortality was 91% in the surgery alone group. The 2-year survival rate was 24%, and the 4-year survival rate was 8%. Preoperative DDP, 5FU combined chemotherapy group 16 cases, complete remission after chemotherapy 1 case (16%), partial remission 5 cases (31%), invalid 10 cases (63%), 12 cases of surgical resection, 1 case due to chemotherapy-related death One patient died of surgery, and the survival rate at 2 and 4 years was 42%. In the preoperative DDP, ADM, and VP16 combined chemotherapy group, 22 patients received complete remission (5%) after chemotherapy, 11 patients partially resolved (50%), 10 patients did not respond (45%), and 18 patients had surgical resection without operative mortality. The 2-year survival rate is 58%. [Conclusion] Preoperative chemotherapy can significantly improve the survival rate of patients with esophageal adenocarcinoma, and the treatment should be individualized.